FDA Updates Rule on Animal Testing for New Drugs
National News - The U.S. Food and Drug Administration has issued a new rule about how drugs are tested before they reach humans. The rule allows non-animal methods to be used when appropriate to test the safety of drugs and biological products.
This change reflects advances in science and technology. Scientists now have more testing options, including human cell studies, organ-on-chip technology and computer models.
Acting FDA Commissioner Kyle Diamantas, J.D., explained the reasoning behind the update. "This new rule supports the Trump Administration's push to explore ways to complement, or where appropriate, replace animal studies with methods that may better predict how medicines will actually affect people," Diamantas said. "It gives scientists and drug developers greater flexibility to use the testing approach that best addresses their scientific question. Our goal is not to replace one rigid approach with another. It is to support rigorous, modern science - including animal studies when they remain appropriate and validated alternatives when they can provide the evidence needed to protect patients."
The rule also changes some of the wording the FDA uses. Terms like "animal tests" and "animal studies" are now replaced with "nonclinical tests" and "nonclinical studies."
These new terms match definitions already set out in the Food and Drug Omnibus Reform Act of 2022. That law recognized newer testing methods as valid ways to support the start of human drug trials.
The FDA said the rule does not ban or remove animal testing. It only removes language suggesting animal testing is the only acceptable way to gather safety information.
Officials also said the rule does not add new costs or requirements for drug developers. It simply gives them more options to choose from.
To show how these methods work in practice, the FDA launched a new database. It includes 25 examples of New Approach Methodologies, known as NAMs, pulled from public FDA review records.
The FDA said this work supports its Innovation and Global Leadership goals. The agency hopes clearer rules will help drug developers move forward with less uncertainty.
The effort also connects to Operation TrialBlazer, a Department of Health and Human Services program. That program is working to modernize clinical research and speed up the development of new treatments.
The FDA is now asking the public to weigh in on the new rule. Clinicians, parents, caregivers, scientists and industry members can all submit comments during the review period.
If the FDA receives significant pushback during that period, the agency said it will withdraw the direct final rule. In that case, it will continue the process through standard rulemaking instead.
